Europäische Union - Litauisch - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - rekombinantinis vezikulinio stomatito virusas (padermės indiana) su ištrinti voko glikoproteinas, pakeista zairas ebolavirus (padermės kikwit 1995) paviršiaus glikoproteino - hemoraginės karštligės, ebola - vakcinos - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. naudoti ervebo turėtų būti laikantis oficialių rekomendacijų.

Europäische Union - Litauisch - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - imipenem monohidratas, cilastatin natrio, relebactam monohidratas - gram-neigiamų bakterijų infekcijos - carbapenems, antibacterials for systemic use, - recarbrio is indicated for:- treatment of hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap), in adults (see sections 4. 4 ir 5. - treatment of bacteraemia that occurs in association with, or is suspected to be associated with hap or vap, in adults. - treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4. 2, 4. 4 ir 5. reikėtų atsižvelgti į oficialius nurodymus, kaip tinkamai naudoti antibakterinių veiksnių.

Europäische Union - Litauisch - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - pneumococcal polysaccharide conjugate vaccine (adsorbed) - pneumokokinės infekcijos - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. Žr. 4 skyrius. 4 ir 5. 1 informacijos apie apsaugą nuo konkrečių serotipai. the use of vaxneuvance should be in accordance with official recommendations.

Europäische Union - Litauisch - EMA (European Medicines Agency)

merck sharp & dohme b.v. - gefapixant - cough - kosulys ir šalčio preparatai - lyfnua is indicated in adults for the treatment of refractory or unexplained chronic cough.